Line 1,514: |
Line 1,514: |
| | | | | |
| | | | | |
− | | ||Snehal Patel (SP) | + | | ||Sumi Kitahara (SK) |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |T-cell Prolymphocytic Leukemia||Disease||Michelle Don | | |T-cell Prolymphocytic Leukemia||Disease||Michelle Don |
Line 1,522: |
Line 1,522: |
| | | | | |
| |PENDING | | |PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |T-cell Large Granular Lymphocytic Leukemia||Disease||Michelle Don | | |T-cell Large Granular Lymphocytic Leukemia||Disease||Michelle Don |
Line 1,530: |
Line 1,530: |
| | | | | |
| |PENDING | | |PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |Chronic Lymphoproliferative Disorder of NK Cells||Disease||Michelle Don | | |Chronic Lymphoproliferative Disorder of NK Cells||Disease||Michelle Don |
Line 1,538: |
Line 1,538: |
| | | | | |
| |PENDING | | |PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |Aggressive NK-cell Leukemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD | | |Aggressive NK-cell Leukemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD |
Line 1,546: |
Line 1,546: |
| | | | | |
| |?PENDING | | |?PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood'''''||'''''Overview'''''|| | | |'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood'''''||'''''Overview'''''|| |
Line 1,554: |
Line 1,554: |
| | | | | |
| | | | | |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Systemic EBV-Positive T-cell Lymphoma of Childhood||Disease||Lisa Lansdon (trainee) | | | Systemic EBV-Positive T-cell Lymphoma of Childhood||Disease||Lisa Lansdon (trainee) |
Line 1,562: |
Line 1,562: |
| | | | | |
| |Complete | | |Complete |
− | |11/21/2021||SP | + | |11/21/2021||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form||Disease|| | | | Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form||Disease|| |
Line 1,570: |
Line 1,570: |
| | | | | |
| | | | | |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease|| | | | Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease|| |
Line 1,578: |
Line 1,578: |
| | | | | |
| | | | | |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Severe Mosquito Bite Allergy||Disease|| | | | Severe Mosquito Bite Allergy||Disease|| |
Line 1,586: |
Line 1,586: |
| | | | | |
| | | | | |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |Adult T-cell Leukemia/Lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG | | |Adult T-cell Leukemia/Lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG |
Line 1,594: |
Line 1,594: |
| | | | | |
| |?PENDING | | |?PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |Extranodal NK/T-cell Lymphoma, Nasal Type||Disease|| | | |Extranodal NK/T-cell Lymphoma, Nasal Type||Disease|| |
Line 1,602: |
Line 1,602: |
| | | | | |
| | | | | |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |'''''Intestinal T-cell Lymphoma'''''||'''''Overview'''''||Sumire Kitahara, Derick Okwan (trainee) | | |'''''Intestinal T-cell Lymphoma'''''||'''''Overview'''''||Sumire Kitahara, Derick Okwan (trainee) |
Line 1,611: |
Line 1,611: |
| |Complete | | |Complete |
| |9/26/2022 | | |9/26/2022 |
− | |SP | + | |SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Enteropathy-Associated T-cell Lymphoma||Disease||Sumire Kitahara, Derick Okwan (trainee) | | | Enteropathy-Associated T-cell Lymphoma||Disease||Sumire Kitahara, Derick Okwan (trainee) |
Line 1,620: |
Line 1,620: |
| |Complete | | |Complete |
| |1/21/2021 | | |1/21/2021 |
− | |SP | + | |SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Monomorphic Epitheliotropic Intestinal T-cell Lymphoma||Disease||Sumire Kitahara | | | Monomorphic Epitheliotropic Intestinal T-cell Lymphoma||Disease||Sumire Kitahara |
Line 1,629: |
Line 1,629: |
| |PENDING | | |PENDING |
| | | | | |
− | |SP | + | |SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Sumire Kitahara, Derick Okwan (trainee) | | | Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Sumire Kitahara, Derick Okwan (trainee) |
Line 1,638: |
Line 1,638: |
| |Complete | | |Complete |
| |9/26/2022 | | |9/26/2022 |
− | |SP | + | |SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract||Disease||Sumire Kitahara, Derick Okwan (trainee) | | | Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract||Disease||Sumire Kitahara, Derick Okwan (trainee) |
Line 1,647: |
Line 1,647: |
| |PENDING | | |PENDING |
| | | | | |
− | |SP | + | |SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |Hepatosplenic T-cell Lymphoma||Disease||Michelle Don | | |Hepatosplenic T-cell Lymphoma||Disease||Michelle Don |
Line 1,656: |
Line 1,656: |
| |Complete | | |Complete |
| |1/21/2021 | | |1/21/2021 |
− | |SP | + | |SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease|| | | |Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease|| |
Line 1,664: |
Line 1,664: |
| | | | | |
| | | | | |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |Mycosis Fungoides||Disease||Daynna Wolff, Jane Scribner (trainee) | | |Mycosis Fungoides||Disease||Daynna Wolff, Jane Scribner (trainee) |
Line 1,672: |
Line 1,672: |
| | | | | |
| |PENDING | | |PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |Sézary Syndrome||Disease||Daynna Wolff, Madison Hannay (trainee), Tingting Barrett (trainee) | | |Sézary Syndrome||Disease||Daynna Wolff, Madison Hannay (trainee), Tingting Barrett (trainee) |
Line 1,680: |
Line 1,680: |
| | | | | |
| |PENDING | | |PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders'''''||'''''Overview'''''||Peining Li, PhD | | |'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders'''''||'''''Overview'''''||Peining Li, PhD |
Line 1,688: |
Line 1,688: |
| | | | | |
| |PENDING | | |PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Lymphomatoid Papulosis||Disease||Peining Li, PhD | | | Lymphomatoid Papulosis||Disease||Peining Li, PhD |
Line 1,696: |
Line 1,696: |
| | | | | |
| |PENDING | | |PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD | | | Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD |
Line 1,704: |
Line 1,704: |
| | | | | |
| |PENDING | | |PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||Peining Li, PhD | | |'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||Peining Li, PhD |
Line 1,712: |
Line 1,712: |
| | | | | |
| |PENDING | | |PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||Peining Li, PhD | | | Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||Peining Li, PhD |
Line 1,720: |
Line 1,720: |
| | | | | |
| |PENDING | | |PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||Peining Li, PhD | | | Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||Peining Li, PhD |
Line 1,728: |
Line 1,728: |
| | | | | |
| |PENDING | | |PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||Peining Li, PhD | | | Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||Peining Li, PhD |
Line 1,736: |
Line 1,736: |
| | | | | |
| |PENDING | | |PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||Peining Li, PhD | | | Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||Peining Li, PhD |
Line 1,744: |
Line 1,744: |
| | | | | |
| |PENDING | | |PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Bo Hong | | |Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Bo Hong |
Line 1,752: |
Line 1,752: |
| | | | | |
| | | | | |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin'''''||'''''Overview'''''|| | | |'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin'''''||'''''Overview'''''|| |
Line 1,760: |
Line 1,760: |
| | | | | |
| | | | | |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Angioimmunoblastic T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee) | | | Angioimmunoblastic T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee) |
Line 1,769: |
Line 1,769: |
| |PENDING | | |PENDING |
| | | | | |
− | |SP | + | |SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Follicular T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee) | | | Follicular T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee) |
Line 1,778: |
Line 1,778: |
| |PENDING | | |PENDING |
| | | | | |
− | |SP | + | |SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype||Disease||Hans Hamnvåg | | | Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype||Disease||Hans Hamnvåg |
Line 1,786: |
Line 1,786: |
| | | | | |
| |PENDING | | |PENDING |
− | | ||SP | + | | ||SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |Anaplastic Large Cell Lymphoma, ALK-Positive||Disease||Sumire Kitahara / Miguel Gonzalez (trainee) | | |Anaplastic Large Cell Lymphoma, ALK-Positive||Disease||Sumire Kitahara / Miguel Gonzalez (trainee) |
Line 1,795: |
Line 1,795: |
| |Completed | | |Completed |
| |09/23/2022 | | |09/23/2022 |
− | |SP | + | |SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |Anaplastic Large Cell Lymphoma, ALK-Negative||Disease||Sumire Kitahara / Miguel Gonzalez (trainee) | | |Anaplastic Large Cell Lymphoma, ALK-Negative||Disease||Sumire Kitahara / Miguel Gonzalez (trainee) |
Line 1,804: |
Line 1,804: |
| |Completed | | |Completed |
| |09/23/2022 | | |09/23/2022 |
− | |SP | + | |SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| |Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||Sumire Kitahara | | |Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||Sumire Kitahara |
Line 1,813: |
Line 1,813: |
| |PENDING | | |PENDING |
| | | | | |
− | |SP | + | |SK |
− | |
| |
| | | | | |
| + | |SP (prior AE) |
| |- | | |- |
| | || || | | | || || |